THE ROLE OF PCSK9 INHIBITORS IN HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES
Keywords:
PCSK9 inhibitors, hyperlipidemia, cardiovascular disease, statins, liver, pharmacokinetics, pharmacodynamicsAbstract
This article examines the role of a new generation of drugs—PCSK9 inhibitors (Evolocumab, Alirocumab)—in the treatment of hyperlipidemia. In particular, their advantages over statins in patients with liver diseases are analyzed from pharmacokinetic and pharmacodynamic perspectives. Research findings indicate that PCSK9 inhibitors significantly reduce levels of LDL (low-density lipoproteins) cholesterol without causing damage to liver enzymes.
Downloads
References
Gallego-Colon E., Daum A., Yosefy C.Statins and PCSK9 inhibitors: A new lipid-lowering therapy.European Journal of Pharmacology, 2020.
Rodriguez F., Harrington R.A.Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.JAMA, 2016.
Khan S.U. et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and meta-analysis.BMJ, 2022.
Coppinger C., Movahed M.R., Azemawah V. et al.A Comprehensive Review of PCSK9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2022.
Mueller Z.T., Craddock K.E., Pitlick J.M.PCSK9 Inhibitors: An Emerging Class of Medications. Journal of Pharmacy Practice, 2016.
NCBI Stat Pearls PCSK9 Inhibitors. National Center for Biotechnology Information (NCBI Bookshelf), 2023.
Taylor B.A., Thompson P.D.Statins and Their Effect on PCSK9 – Impact and Clinical Relevance. Current Atherosclerosis Reports, 2016.
Welder G. et al.Statins and ezetimibe modulate plasma PCSK9 levels. Journal of Lipid Research, 2010.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
